Cancer Biology & Medicine

 


Cancer Biology & Medicine

Cancer Biology & Medicine is a peer-reviewed open-access journal published by the Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:

● Cancer genetics

● Cancer and stem cell biology

● Molecular and clinical immunology

● Cancer prevention and epidemiology

● Cancer biomarkers

● Radiation oncology

● Oncology clinical trials

● Mechanisms of drug sensitivity and resistance

● Targeted therapy and immunotherapy

● Multidisciplinary treatment and personalized medicine

Author Benefits

● Easy submission via online system

● Efficient and professional peer review

● Rapid pre-print online publication

● No charge for publication and open access

● International visibility-All full texts are free in PubMed Central

 

Announcements

 

FIRST IMPACT FACTOR 4.607

 

According to the Journal Citation Reports (2018), we are very pleased to declare that the FIRST IMPACT FACTOR (2017) of Cancer Biology & Medicine is 4.607. It located in Q1 areas both in Medicine, Research & Experimental category (ranking 23/133) and Oncology category (ranking 55/222), respectively.

Click here to learn more on Cancer Biology & Medicine in Journal Citation Reports.


 
Posted: 2018-07-16
 

Publication of the 2nd issue in 2018

 

The second issue of Cancer Biology & Medicine in 2018 has been published. The main contents of the two invited reviews highlight the cancer immunology from different aspects, including the role of microRNA in checkpoint blockade, and PD-1/PD-L1 pathway in cancer therapy. The authors of another review focus on the risk factor of liver cancer, namely liver fibrosis. The researches on molecular mechanism of breast cancer and lung cancer, and the diagnostic values of imaging technology in colorectal malignancy and papillary thyroid cancer have been described in details as original articles. What’s more, two valuable case reports display the crizotinib resistance in lung cancer patients with an EML4-ALK rearrangement, and hypercalcemia in two ovarian cancer patients with different mechanisms, respectively. We hope all of these articles will greatly benefit you on your research and clinical practice, and warmly welcome you to submit studies to Cancer Biology & Medicine.

 

Please click here to learn more.

 

 
Posted: 2018-05-15
 
More Announcements...

Vol 15, No 2: May 2018

Table of Contents

Review

Key questions about the checkpoint blockade-are microRNAs an answer? PDF HTML
Mihnea Dragomir, Baoqing Chen, Xiao Fu, George A. Calin 103-115
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy PDF HTML
Long Jia, Qi Zhang, Rongxin Zhang 116-123
Progress in non-invasive detection of liver fibrosis PDF HTML
Chengxi Li, Rentao Li, Wei Zhang 124-136

Original Article

Enterolactone modulates the ERK/NF-κB/Snail signaling pathway in triple-negative breast cancer cell line MDA-MB- 231 to revert the TGF-β-induced epithelial–mesenchymal transition PDF HTML
Aniket V. Mali, Asavari A. Joshi, Mahabaleshwar V. Hegde, Shivajirao S. Kadam 137-156
Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy PDF HTML
Ye Tian, Changyu Sun, Limeng Zhang, Yuan Pan 157-164
Diagnostic value of whole-body MRI with diffusion-weighted sequence for detection of peritoneal metastases in colorectal malignancy PDF HTML
Huan Zhang, Weixing Dai, Caixia Fu, Xu Yan, Alto Stemmer, Tong Tong, Guoxiang Cai 165-170
Ultrasound features of extranodal extension in the metastatic cervical lymph nodes of papillary thyroid cancer: a case-control study PDF HTML
Jiali Mu, Xiaofeng Liang, Fangxuan Li, Juntian Liu, Sheng Zhang, Jing Tian 171-177

Case Report

Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report PDF HTML
Ling Zhang, Yunxia Li, Shaohong Zhang, Chen Gao, Keke Nie, Youxin Ji 178-181
Ovarian cancer presenting with hypercalcemia: two cases with similar manifestations but different mechanisms PDF HTML
Xuegong Ma, Yingmei Wang, Xuhong Zhang, Mengting Dong, Wen Yang, Fengxia Xue 182-187


OUR FRIENDS